Exabis Library
Welcome to the e-CCO Library!
P326: Audit and review of infliximab therapeutic drug monitoring and prescribing practices in paediatric inflammatory bowel disease (IBD) patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P326: Efficacy of vedolizumab on patient-reported outcomes in ulcerative colitis patients: results from a prospective German observational study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P326: Physicians’ recommendations for travel in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P326: PREFAB-study: PRediction tool for Early identification of patients at risk of Crohn's disease in perianal Fistulas and ABscesses: interim analysis of a prospective pilot study at a non-academic, IBD-expert centre in the Netherlands
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P326: The effect of compliance during exclusive enteral nutrition on faecal calprotectin levels in children with Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P326: Validation of CUCQ-8 Questionnaire for Quality of Life Assessment in IBD Patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P327 Effectiveness of anti-TNF vs. vedolizumab as a second biologic in IBD: results from national Swedish registers
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P327: Biosimilar infliximab in real-life Crohn’s disease’s anti-TNFalfa naïve patients: a comparative observational cohort study (SIMRECRO study)
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P327: Characteristics of esophago-gastro-duodenal Crohn's disease in the biologic era: a nationwide study of the Young GETECCU Group
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P327: Comparison of adalimumab drug levels and drug survival in proactive vs reactive therapeutic drug monitoring
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P327: Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P327: Long-term effectiveness of ustekinumab in refractory Crohn's disease: an Italian multicenter real-life study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P327: Segmental colectomy for ulcerative colitis: a new paradigm? A multi-centric study in 72 patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P327: Symptom relevance attributed by inflammatory bowel disease patients has a differential impact on their quality of life
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P328 Faecal microbiota transplantation as treatment for recurrent Clostridiodes difficile infection in patients with inflammatory bowel disease: Experiences of the Netherlands donor faeces bank
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P328: Crohn’s colitis care (CCCare): development and testing of a bespoke cloud-based clinical management system for inflammatory bowel disease (IBD)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P328: Factors related to short- and long-term treatment results and usefulness of infliximab for refractory ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P328: Holistic well-being as Patient-reported outcomes (PROs) in translational IBD research: Prospective capture of CUCQ32 as study endpoints for mechanistic biomarker MUSIC/GIDAMPs study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P328: In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P328: Low vitamin K, vitamin D and calcium dietary intake in IBD patients represents a potentially reversible risk factor for osteoporosis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM